"THE FDA'S REVIEW OF THE DATA ON OPEN POWER MORCELLATION WAS 'INADEQUATE, IRRESPONSIBLE' AND A 'DISSERVICE TO WOMEN'"
WILLIAM H. PARKER, MD (AUDIO COMMENTARY; NOVEMBER 2014)
In the February issue of OBG Management, you quoted me as saying that the recent FDA analysis of power morcellation was inadequate. Actually, what I said was that the "FDA did an inadequate and irresponsible analysis and it has been a disservice to women." I didn't mince words when I spoke and I am appalled by the FDA's lack of rigor in this important matter.
William H. Parker, MD
Santa Monica, California
* The editors respond
We thank Dr. Parker for expressing his concern to us. Although the full title of Dr. Parker's Web exclusive audio was included online, it was truncated in print due to space and may have not conveyed his full meaning to print readers. Dr. Parker's voice, and how it is portrayed within the journal's pages and online, is very important to us.
ANSWERING YOUR CODING QUESTIONS
A reader recently requested assistance for a specific coding challenge. We've asked our reimbursement specialist, Melanie Witt, RN, CPC, COBGC, MA, to provide her insight.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Comment & Controversy|
|Author:||Parker, William H.|
|Article Type:||Letter to the editor|
|Date:||Apr 1, 2015|
|Previous Article:||Breast cancer survivors should try glycerin-containing products.|
|Next Article:||What billing code for patients with inconclusive viability?|